You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Epitope-directed monoclonal antibody production for mosquito immune cells (for malaria)
SBC: LUNA LABS USA LLC Topic: 118Luna Labs proposes to develop monoclonal antibodies (mAbs) for use in the identification and characterization of mosquito immune cells for immune responses and validation through various immunoassays and surface plasmon resonance (SRP). Since the project focuses on target proteins expressed in mosquito hemocytes that mediate innate cellular and humoral immunity to pathogens, and the antibodies pro ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Affinity Reagents for the Immune System of Golden Hamster (for SARS-CoV-2 induced long-COVID disease)
SBC: QOOLABS INC Topic: 118QooLabs proposes to generate high-affinity monoclonal antibodies against six immune cell targets of Syrian golden hamsters that are relevant to long-COVID research. Specifically, the Offeror proposes to produce recombinant proteins as immunogens for immunization of rabbits, to generate rabbit monoclonal antibodies using their proprietary method, and to validate the antibodies for use in long-COVID ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
SBIR TOPIC 107, PHASE II, TRANSCATHETER POTTS SHUNT
SBC: TRANSMURAL SYSTEMS LLC Topic: 107Phase II award for continued development of a catheter system to establish a non-surgical Potts Shunt (transcatheter pulmonary-to-aortic anastomosis) to treat refractory pulmonary artery hypertension.
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
PROVIRAL SEQUENCING DRIVEN DEVELOPMENT OF ENHANCED IPDAV2 WITH GLOBAL HIV-1 GROUP M COVERAGE TO SUPPORT WORLDWIDE CURE AND CLINICAL TRIALS
SBC: ACCELEVIR DIAGNOSTICS LLC Topic: 78The objective of this program is to develop and commercialize sequence-based HIV reservoir assays for clinical HIV cure interventions. The assay should be designed as an analytical tool to monitor the size of the replication-competent HIV reservoir in clinical research and in prospective clinical trials. An additional goal of the program is to develop secondary assays that are not tissue culture-b ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
""THE EV-HIV ASSAY, A POINT-OF-CARE LATERAL FLOW IMMUNOASSAY TO ACCURATELY IDENTIFY HIV INFECTION FROM BLOOD-BASED EXTRACELLULAR VESICLES""
SBC: Intuitive Biosciences, Inc. Topic: 115Development of Diagnostics to Differentiate HIV Infection from Vaccine-Induced Seropositivity: The overarching goal of this program is to support the development of new serological and nucleic acid assays that can identify HIV infection while avoiding false-positive results due to vaccine-induced seropositivity (VISP), with high sensitivity and specificity. These next generation assays should be d ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
""MULTIPLEXED DROPLET DIGITAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES FOR HIV DIAGNOSIS""
SBC: Fluid Discovery Inc Topic: 115Development of Diagnostics to Differentiate HIV Infection from Vaccine-Induced Seropositivity: The overarching goal of this program is to support the development of new serological and nucleic acid assays that can identify HIV infection while avoiding false-positive results due to vaccine-induced seropositivity (VISP), with high sensitivity and specificity. These next generation assays should be d ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
""A MULTIFUNCTIONAL POINT-OF-CARE PLATFORM TO DIFFERENTIATE HIV INFECTION FROM VACCINE INDUCED SEROPOSITIVITY""
SBC: BAEBIES, INC. Topic: 115Development of Diagnostics to Differentiate HIV Infection from Vaccine-Induced Seropositivity: The overarching goal of this program is to support the development of new serological and nucleic acid assays that can identify HIV infection while avoiding false-positive results due to vaccine-induced seropositivity (VISP), with high sensitivity and specificity. These next generation assays should be d ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
RAPID POINT-OF-CARE HIV VIRAL LOAD TEST
SBC: LYNNTECH INC. Topic: 114Point-of-Care HIV Viral Load, Drug Resistance, and Adherence Assays: The long-term goals of this program are to develop novel, low-cost, real-time point-of-care (POC) assays for 1. HIV Viral Load Monitoring; 2. HIV Drug Resistance Monitoring; and 3. Pharmacological Adherence Monitoring. This contract aims to develop a device-free, disposable HIV viral load test that can be used as a home-test or i ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
AWARD PINMED SBIR TOPIC #114 PHASE I- Device to Permit Continuous Self-Monitoring of Blood Oxygen Saturation During Activities of Daily Living for Individuals at Risk for Desaturation During Physical Exertion
SBC: PinMed, Inc. Topic: 114The goal of this Phase I topic proposal from Pinmed, Inc is to develop a novel wireless pulse oximeter device for at-home use that is suitable for wear during physical activity and sleep.
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
POINT-OF-CARE MONITORING OF ADHERENCE TO ANTIRETROVIRAL HIV THERAPY
SBC: GINER INC Topic: 114Point-of-Care HIV Viral Load, Drug Resistance, and Adherence Assays: The long-term goals of this program are to develop novel, low-cost, real-time point-of-care (POC) assays for 1. HIV Viral Load Monitoring; 2. HIV Drug Resistance Monitoring; and 3. Pharmacological Adherence Monitoring. This contract aims to develop an electrochemical POC test that will enable direct and label-free measurement of ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health